Search Results 441-450 of 17269 for SC
Blumenthal, M.D.. Cardiologist. Jacksonville, FL. Kimberly ...
The purpose of this study is to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in ...
Post Doctoral Fellowship - Pulmonary and Critical Care FellowMedical University of South Carolina. 2013. Resident - Post Doctoral Medical Resident Medical ...
... (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy per ...
Olson B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, Graves J, Vallecillo T, Ma DJ, Neben-Wittich MA, Lester SC, Gamez M, Holtzmann A, Mohammadi H, Garcia J ...
This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Solution. Back to top ...
Participants will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks. Participation eligibility. Participant ...
... SC, Bround MJ, Sargent MA, Adams CM, Molkentin JD. Thbs1 regulates skeletal muscle mass in a TGFbeta-Smad2/3-ATF4-dependent manner. Cell Rep. 2024 May 28 ...
The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...
... South Carolina. Areas of clinical expertise include: Management of patients with risk factors for cardiovascular disease; Management of patients with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!